From Financial Modeling Prep: 2025-04-29 07:00:00

AstraZeneca reported an EPS of $1.25, beating estimates, showcasing strong financial performance. However, revenue fell short of expectations at $13.59 billion, with a ‘soft’ performance in China contributing to the shortfall. The company’s oncology portfolio drove growth, maintaining full-year guidance despite potential legal challenges in China.



Read more at Financial Modeling Prep:: AstraZeneca’s (NASDAQ:AZN) Earnings Report Highlig…